ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will present at the 24th Annual ROTH Capital Conference held March 11-14, 2012 at The Ritz Carlton in Dana Point, CA.
